CRISPR/Cas9: A Brief Introduction and Applications in Cancer
DOI:
https://doi.org/10.61173/btzks160Keywords:
CRISPR/Cas9, gene editing, development, cancerAbstract
CRISPR/Cas9 is a relatively new technology for gene knockout developed from prokaryotic immune mechanisms against exogenous DNA. The technology has been extensively used in cancer research and therapy development. CRISPR/Cas9 as a relatively in-mature gene editing tool with certain limitations, has shown great potential in applications in a variety of fields. In this review, a basic and brief introduction of the technology and its application in cancer research and therapy development will be given. This includes the principles and development of the technology, genetic screens using CRISPR/Cas9 finding new therapy targets, its use in gene therapies, its role in creating modified cells immunotherapies, some works that have been done in these fields and the future possibilities of the technology. This review aims at providing a basic and rudimentary understanding of CRISPR/Cas9 as well as its applications in cancer. And perhaps give some insight for future studies regarding the technology and its applications in cancer.References
[1] Ishino Y, Shinagawa H, Makino K, et al. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol. 1987;169:5429-5433.
[2] Gostimskaya I. CRISPR-Cas9: A history of its discovery and ethical considerations of its use in genome editing. Biochemistry (Mosc). 2022 Aug;87(8):777-788.
[3] Horodecka K, Düchler M. CRISPR/Cas9: Principle, applications, and delivery through extracellular vesicles. Int J Mol Sci. 2021 Jun 4;22(11):6072.
[4] Wang SW, Gao C, Zheng YM, et al. Current applications and future perspective of CRISPR/Cas9 gene editing in cancer. Mol Cancer. 2022 Feb 21;21(1):57.
[5] Pourcel C, Touchon M, Villeriot N, et al. CRISPRCasdb: A successor of CRISPRdb containing CRISPR arrays and cas genes from complete genome sequences, and tools to download and query lists of repeats and spacers. Nucleic Acids Res. 2020;48
[6] Bolotin A, Quinquis B, Sorokin A, Ehrlich SD. Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology. 2005;151:2551-2561.
[7] Pourcel C, Salvignol G, Vergnaud G. CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for Dean&Francis Yuan Yao evolutionary studies. Microbiology. 2005;151:653-663.
[8] Mojica FJ, Díez-Villaseñor C, García-Martínez J, Soria E. Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol. 2005;60:174- 182..
[9] Brouns SJ, Jore MM, Lundgren M, et al. Small CRISPR RNAs guide antiviral defense in prokaryotes. Science. 2008;321:960-964.
[10] Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816-821.
[11] Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339:823-826.
[12] Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819- 823.
[13] Jinek M, East A, Cheng A, et al. RNA-programmed genome editing in human cells. eLife. 2013;2:1-9.
[14] Cho SW, Kim S, Kim JM, Kim JS. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol. 2013;31:230-232.
[15] Hwang WY, Fu Y, Reyon D, et al. Efficient genome editing in zebrafish using a CRISPR–Cas system. Nat Biotechnol. 2013;31:227-229.
[16] Wilbie D, Walther J, Mastrobattista E. Delivery aspects of CRISPR/Cas for in vivo genome editing. Acc Chem Res. 2019;52:1555-1564.
[17] Brown BD, Sitia G, Annoni A, et al. In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood. 2007;109:2797-2805.
[18] Shalem O, Sanjana NE, Hartenian E, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84-87.
[19] Wang T, Wei JJ, Sabatini DM, Lander ES. Genetic screens in human cells using the CRISPR-Cas9 system. Science. 2014;343:80-84.
[20] Zhou Y, Zhu S, Cai C, et al. High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature. 2014;509:487-491.
[21] Yamauchi T, Masuda T, Canver MC, et al. Genome-wide CRISPR-Cas9 screen identifies leukemia-specific dependence on a pre-mRNA metabolic pathway regulated by DCPS. Cancer Cell. 2018;33:386-400.e385.
[22] Matano M, Date S, Shimokawa M, et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med. 2015;21:256-262.
[23] Tzelepis K, Koike-Yusa H, De Braekeleer E, et al. A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia. Cell Rep. 2016;17:1193-1205.
[24] Shang W, Jiang Y, Boettcher M, et al. Genome-wide CRISPR screen identifies FAM49B as a key regulator of actin dynamics and T cell activation. Proc Natl Acad Sci U S A. 2018;115
[25] .Xue W, Chen S, Yin H, et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature. 2014;514:380-384.
[26] Wang J, Quake SR. RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proc Natl Acad Sci U S A. 2014;111:13157-13162.
[27] Khan FA, Pandupuspitasari NS, Chun-Jie H, et al. CRISPR/ Cas9 therapeutics: A cure for cancer and other genetic diseases. Oncotarget. 2016 Aug 9;7(32):52541-52552.
[28] White MK, Khalili K. CRISPR/Cas9 and cancer targets: Future possibilities and present challenges. Oncotarget. 2016 Mar 15;7(11):12305-12317.
[29] Sadelain M, Rivière I, Brentjens R. Targeting tumors with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3:35-45.
[30] Wang X, Rivière I. Clinical manufacturing of CAR T cells: Foundation of a promising therapy. Mol Ther Oncolytics. 2016;3:16015.
[31] Torikai H, Reik A, Liu PQ, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood. 2012;119:5697-5705.
[32] Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumor rejection. Nature. 2017;543:113-117.
[33] Bendle GM, Linnemann C, Hooijkaas AI, et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med. 2010;16:565-570.
[34] Legut M, Dolton G, Mian AA, et al. CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells. Blood.
[35] Zhang C, Peng Y, Hublitz P, et al. Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy. Sci Rep. 2018;8:5549.
[36] Zhang W, Shi L, Zhao Z, et al. Disruption of CTLA-4 expression on peripheral blood CD8+ T cells enhances antitumor efficacy in bladder cancer. Cancer Chemother Pharmacol. 2019;83:911-920.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
